Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation
- 22 August 2008
- journal article
- clinical trial
- Published by Elsevier BV in Cancer Letters
- Vol. 272 (2), 221-225
- https://doi.org/10.1016/j.canlet.2008.07.008
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapyBritish Journal of Cancer, 2007
- Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant TreatmentJournal of Clinical Oncology, 2006
- Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal CancerJournal of Clinical Oncology, 2005
- Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patientsBritish Journal of Cancer, 2005
- Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5‐FU‐based neo‐adjuvant chemoradiotherapy in rectal cancerThe Journal of Pathology, 2004
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levelsPharmacogenetics, 2004
- Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapyThe Pharmacogenomics Journal, 2001
- Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.Journal of Clinical Oncology, 1997
- Chemotherapy for Colorectal CancerNew England Journal of Medicine, 1994